证券研究报告：电子 | 公司点评报告 股票投资评级 买入 |首次覆盖 个股表现 2025-02 2025-04 2025-07 2025-09 2025-11 2026-02 -26% -9% 8% 25% 42% 59% 76% 93% 110% 127% 144% 联动科技 电子 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 116.22 | | --- | --- | | 总股本/流通股本（亿股）0.71 | / 0.36 | | 总市值/流通市值（亿元）82 | / 42 | | 52 周内最高/最低价 | 142.94 / 43.10 | | 资产负债率(%) | 6.1% | | 第一大股东 | 张赤梅 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 研究助理:陈天瑜 SAC 登记编号:S1340125090015 Email:chentianyu@cnpsec.com 联动科技(301369) 大算力 SoC 测试机加速推进 l 投资要点 营收稳健增长，股份支付短期影响业绩表现。2025 年前 ...

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 22.22 CNY per share based on a PE of 37x for 2026 [5]. Core Views - The global demand for gas turbines is on the rise, which is expected to accelerate the revenue growth of the company's waste heat boilers. The AIDC catalytic gas turbine industry is projected to see significant growth, with demand in the U.S. expected to increase from 4.1 GW to 57.9 GW between 2025 and 2028, with growth rates of 219%, 135%, and 88% in 2026, 2027, and 2028 respectively [2]. - The company is a leader in the domestic waste heat boiler market, holding over 50% market share, and is expanding its presence in overseas markets, particularly in regions along the Belt and Road Initiative [2]. - The company has a strong foothold in the solar thermal power sector, with a market share of 58% in total design capacity and 55% in project numbers for significant solar thermal projects in China from 2021 to 2024 [3]. - The nuclear power sector is also seeing a revival, with the company planning to expand its nuclear power business and has already supplied numerous components to major nuclear power groups [4]. Summary by Sections Section 1: Company Overview - The company has evolved from a traditional waste heat boiler leader to a comprehensive supplier of clean energy equipment, with a history of nearly 50 years in the industry [15]. - It has diversified its business into nuclear power and molten salt energy storage, participating in significant projects and partnerships [15][16]. Section 2: Waste Heat Boilers - The demand for waste heat boilers is expected to rise alongside the gas turbine industry, with the company positioned to benefit from this trend [2]. - The company has seen a 16.81% year-on-year increase in new waste heat boiler orders, amounting to 1.967 billion CNY in 2025 [2][19]. Section 3: Molten Salt Energy Storage - The company is well-positioned to benefit from the growing solar thermal power market in China, with significant policy support and projected capacity growth [3]. - The company has established deep collaborations with leading clients in the solar thermal sector, enhancing its order prospects [3]. Section 4: Nuclear Power - The approval of nuclear power units in China is on the rise, which is expected to drive demand for nuclear equipment [4]. - The company has a long-standing partnership with major nuclear power groups and is expanding its capabilities in advanced nuclear technologies [4]. Section 5: Financial Forecast and Valuation - The company is projected to achieve revenues of 6.3 billion CNY in 2025, 7.3 billion CNY in 2026, and 8.5 billion CNY in 2027, with corresponding net profits of 431 million CNY, 502 million CNY, and 571 million CNY [5][8]. - The company’s PE ratios are expected to decrease from 35x in 2025 to 26x in 2027, reflecting its growth potential and market positioning [5].

证券研究报告：电子 | 公司点评报告 股票投资评级 买入 |首次覆盖 个股表现 2025-02 2025-04 2025-07 2025-09 2025-11 2026-02 -21% -1% 19% 39% 59% 79% 99% 119% 139% 159% 方邦股份 电子 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 84.00 | | --- | --- | | 总股本/流通股本（亿股）0.82 | / 0.82 | | 总市值/流通市值（亿元）69 | / 69 | | 52 周内最高/最低价 | 95.70 / 27.70 | | 资产负债率(%) | 22.5% | | 第一大股东 | 胡云连 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 研究助理:陈天瑜 SAC 登记编号:S1340125090015 Email:chentianyu@cnpsec.com 方邦股份(688020) 发布时间：2026-02-09 薄介电层 FCCL 等前沿产品的开发与下游测试认证工作。未来公司将 进一步强 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5]. Core Insights - The company is a leading player in the Chinese tool export market, continuously enhancing its brand and product matrix, resulting in sustained revenue and profit growth. The company has established its own brands and acquired leading brands in niche tool sectors, forming a comprehensive product lineup that includes hand tools, power tools, and industrial tools. From 2011 to 2024, the company's revenue CAGR is projected at 15.95%, while the net profit CAGR is expected to be 17.76% [1][3]. Summary by Sections Company Overview - The company has a stable ownership structure, with the controlling shareholder holding stakes in four listed companies. The controlling shareholder, Mr. Qiu Jianping, holds 38.82% of the company through Juxing Holdings [13]. Industry Outlook - The tool industry is expected to benefit from a recovery in the U.S. real estate market and a replenishment cycle among large retailers. The global tool market is projected to grow from $62.2 billion in 2024 to $67.3 billion by 2026, with a CAGR of 4.02%. The power tool market is expected to grow at a CAGR of 5.51% during the same period [2][46]. Product and Brand Strategy - The company focuses on product innovation and global capacity expansion, with OBM revenue share increasing to 46.39% in the first half of 2025. The company plans to launch over 1,000 new products, including various tool series, and has expanded its production bases in Southeast Asia [3][19][21]. Financial Projections - Revenue projections for 2025-2027 are estimated at 150.58 billion, 185.87 billion, and 215.74 billion yuan, respectively. Net profit is expected to be 25.61 billion, 31.49 billion, and 37.18 billion yuan for the same period [4][5]. Market Position - The company has a significant international presence, with over 90% of its revenue coming from overseas markets. The Americas accounted for 65% of revenue, while Europe contributed 25.66% [34][42]. The company has established a comprehensive global production and supply chain management system, which helps reduce costs and improve delivery capabilities [19][22]. Profitability - The company's gross margin has shown a steady increase, reaching 33.08% in the first three quarters of 2025, the highest level in its history. The gross profit is projected to grow from 5.73 billion yuan in 2011 to 47.37 billion yuan in 2024 [27][30]. The net profit margin is also expected to improve due to the expansion of OBM business and product innovation [42][43].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 31.36, reflecting a valuation premium due to the recent approval of the D-allohexose enzyme preparation [6][4]. Core Insights - The approval of the D-allohexose enzyme preparation as a food additive accelerates the domestic market's growth, positioning the company as a leader in the allohexose sector with significant advantages in capacity and technology [1][2]. - The company is expected to benefit from the increasing health trends, with its prebiotic and dietary fiber businesses gaining traction both domestically and internationally [1][3]. - The company has a current production capacity of 15,000 tons, ranking first in China and second globally, with anticipated new capacity coming online in the first half of 2026, which is expected to drive revenue growth [2][3]. Summary by Sections Company Overview - The company is a leader in the allohexose market and has a strong competitive edge in production capacity and technology, particularly in crystal products [1]. - The company is also a leader in functional sugars, benefiting from the rising health consciousness among consumers [1]. Market Dynamics - Supply-side dynamics indicate that while many companies plan to expand production, high investment costs and immature processes may lead to relatively rational supply growth [2]. - On the demand side, leading companies are beginning to industrialize the new generation of healthy sweeteners, with notable brands like Mengniu Dairy incorporating D-allohexose into their products [2]. Financial Projections - The company is projected to achieve revenues of RMB 1,737 million in 2026, reflecting a growth rate of 25.99% from the previous year [11]. - Net profit attributable to the parent company is expected to reach RMB 470.81 million in 2026, with an EPS forecast of RMB 1.12 [11]. - The report anticipates a stable growth trajectory for the company's prebiotic business and continued high growth in its allohexose overseas operations [3][4]. Valuation Metrics - The report maintains the earnings per share (EPS) estimates at RMB 0.87 for 2025 and RMB 1.12 for 2026, with a price-to-earnings (PE) ratio of 28x for 2026, reflecting a premium valuation due to market expansion prospects [4][11]. - The company’s market capitalization is approximately RMB 11,256 million, with a closing price of RMB 26.80 as of February 6, 2026 [8].

Investment Rating - The report assigns a rating of "Outperform" to the company, indicating a positive outlook for its stock performance relative to the market [2][8]. Core Insights - The company reported a revenue of 1.058 billion yuan for 2025, reflecting a year-on-year growth of 21.8%, and a net profit attributable to shareholders of 237 million yuan, up 33.9% [5][8]. - In Q4 2025, the company achieved a revenue of 262 million yuan, a 21.5% increase year-on-year, and a net profit of 78 million yuan, which is a 26.4% increase [5][8]. - The company is expanding its generic drug product line while simultaneously advancing its new drug development, with a focus on cost reduction and efficiency improvements [5][8]. Financial Data and Profit Forecast - The company’s total revenue is projected to be 1.171 billion yuan in 2026, with a slight decrease to 1.110 billion yuan in 2027 [7]. - The net profit forecast for 2025 is 237 million yuan, followed by 174 million yuan in 2026 and 140 million yuan in 2027, indicating a decline in profitability in the following years [7][9]. - The company’s gross margin is expected to decrease from 83.4% in 2025 to 71.6% in 2027, reflecting potential pricing pressures from market competition [7]. Generic Drug Business - The sales of core products such as "复瑞彤" and "波开清" are steadily increasing, driving growth for the company [8]. - The company is proactively expanding its portfolio of generic drugs, with eight new drug registration approvals obtained in 2025 [8]. Innovative Drug Business - The company is advancing its pipeline of innovative drugs, with the DYX116 project progressing as expected, having completed Phase I clinical trials [8]. - The market for GLP-1 drugs in China is projected to reach 609 billion yuan by 2030, indicating significant growth potential for the company’s innovative drug offerings [8].

Investment Rating - The investment rating for the company is "Buy" [1][8] Core Insights - The company, Zhao Feng Co., is a leading manufacturer of automotive wheel hub bearings, with a dual-driven strategy focusing on both aftermarket and OEM markets. It has established a strong presence in the high-end market in Europe and the US since its inception in 1997 and has diversified into the robotics sector through a unique model of "industrial investment + core component manufacturing + downstream applications" [4][6][12]. Company Overview - Zhao Feng Co. has a clear development trajectory, transitioning from a focus on automotive wheel hub bearings to diversifying into robotics and other new sectors. The company has established a dual-driven strategy since 2018, emphasizing both aftermarket and OEM business, and has made significant progress in the domestic market [15][16][20]. - The company's main business is automotive wheel hub bearings, which accounted for approximately 92% of revenue in 2024. It has developed over 5,500 types of wheel hub bearings, covering a wide range of vehicles from micro to heavy-duty and including traditional and new energy vehicles [22][23][59]. Financial Performance - The company is expected to achieve a net profit attributable to shareholders of 378 million yuan in 2025, 410 million yuan in 2026, and 530 million yuan in 2027, with corresponding P/E ratios of 20.8, 19.2, and 14.8 respectively [8][10]. - In the first half of 2025, the company reported a revenue of 5.11 billion yuan, a year-on-year increase of 5.17%, and a net profit of 3.03 billion yuan, reflecting a significant recovery [34]. Industry Insights - The automotive wheel hub bearing market is expected to grow significantly, driven by increasing vehicle production and the rising demand for high-performance components in electric and intelligent vehicles. The global market size for wheel hub bearings is projected to reach 759.4 billion yuan in 2024, with China's market expected to grow to 227.6 billion yuan [46][49]. - The company is well-positioned in the high-margin segment of the wheel hub bearing market, benefiting from its focus on high-end products and advanced manufacturing capabilities, which include automation and smart manufacturing [50][54]. Strategic Investments - Zhao Feng Co. has made strategic investments in leading robotics companies, establishing deep collaborations to enhance its position in the robotics supply chain. The company aims to create a closed-loop ecosystem around core components, assemblies, and applications in the robotics sector [63][68]. - The partnership with Leju Intelligent and other robotics firms aims to leverage manufacturing strengths and cutting-edge technology to develop key robotic components, enhancing the company's competitive edge in the rapidly growing robotics market [69][70].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking the first coverage of the stock [5]. Core Insights - The company has seen a significant increase in overseas orders, with new contracts amounting to 7.2 billion yuan in 2025, representing a year-on-year growth of 140.1%. In Q4 alone, new overseas orders reached 2.2 billion yuan, a staggering increase of 568.4% [4]. - The company has demonstrated continuous improvement in cash flow, with operating net cash flow rising from -243 million yuan in 2021 to 771 million yuan in 2024. The cash collection ratio improved to 112.06% in the first three quarters of 2025, indicating strong cash management [4]. - A shareholder return plan was announced, projecting an average net profit of 680 million yuan from 2025 to 2027, with a commitment to distribute at least 70% of the annual net profit or a minimum of 400 million yuan in dividends, enhancing the company's high dividend yield profile [4]. Summary by Sections Financial Data - Total market capitalization is 9,254.08 million yuan, with a 52-week high of 4.75 yuan and a low of 2.96 yuan. The stock has seen a 52-week increase of 57.09% [4]. Profit Forecast - Expected net profits for 2025, 2026, and 2027 are projected at 629 million yuan, 729 million yuan, and 826 million yuan respectively, with corresponding P/E ratios of 14.71, 12.70, and 11.20 [6].

Investment Rating - The report maintains a "Buy" rating for Shanxi Fenjiu [1] Core Insights - Shanxi Fenjiu is positioned as a leading brand in the clear aroma liquor segment, benefiting from differentiated flavor profiles, national expansion, and a multi-price product strategy, with a significant growth potential projected to reach 600-700 billion RMB in revenue in the medium to long term [13][14] - The company is actively exploring brand rejuvenation and targeting younger consumers through innovative marketing strategies and product offerings [22][28] - The nationalization strategy 2.0 is being implemented, focusing on deepening market penetration and optimizing product management across various regions [30][33] Summary by Sections 1. Clear Aroma Liquor Expansion - The clear aroma liquor segment is expected to grow significantly, with Shanxi Fenjiu's market share projected to increase from 0.7% to 4.5% from 2016 to 2024 [20] - The company is targeting a "three-way split" market structure in the next high-end price segment, with substantial growth opportunities identified [20][21] 2. Multi-Price Product Strategy - Shanxi Fenjiu has a diverse product portfolio across various price segments, which enhances its growth potential and resilience against market fluctuations [51] - The company has introduced a "four-wheel drive" strategy for product management, focusing on key product lines to optimize resource allocation [53][54] 3. Channel Management and Organizational Efficiency - The company has refined its channel management through the "Fen Enjoy Benefits" system, which enhances pricing stability and incentivizes sales performance [19][30] - Shanxi Fenjiu's sales team remains stable, with a clear career progression path that fosters motivation and productivity among frontline sales personnel [19][30] 4. Financial Projections - Revenue forecasts indicate a steady growth trajectory, with total revenue expected to reach 37,875 million RMB in 2026, and net profit projected at 12,416 million RMB [1] - The company's earnings per share (EPS) is anticipated to grow from 10.04 RMB in 2024 to 10.18 RMB in 2026, reflecting a positive outlook for profitability [1]

Investment Rating - The report assigns a rating of "Buy" to the company with a target price of 262.35 CNY, compared to the current price of 221.01 CNY [5]. Core Insights - The company is expected to benefit from the rapid growth in the optical communication market driven by AI computing demands, with projected revenues of 5.92 billion CNY, 7.68 billion CNY, and 9.81 billion CNY for 2025-2027, respectively [10]. - The net profit forecast for the same period is 870 million CNY, 1.28 billion CNY, and 1.71 billion CNY, with EPS of 0.68 CNY, 0.99 CNY, and 1.32 CNY [10]. - The global optical module market is projected to reach approximately 25 billion USD by 2029, with a CAGR of 15% from 2023 to 2029, primarily driven by strong demand from AI applications [10]. Financial Summary - Total revenue is forecasted to be 340 million CNY in 2023, increasing to 981 million CNY by 2027, reflecting a growth rate of 31% in 2024 and 33% in 2025 [4]. - Net profit attributable to the parent company is expected to rise from 42 million CNY in 2023 to 171 million CNY in 2027, with a significant increase of 66.5% in 2024 [4]. - The company’s PE ratio is projected to decrease from 686.28 in 2023 to 167.50 in 2027, indicating improving valuation metrics [4]. Company Overview - The company, established in October 2013, specializes in the research, production, and sales of precision optical components, fiber optic devices, and optical testing instruments, with applications in optical communication and fiber lasers [14]. - The company has a strong technical foundation with multiple core technology platforms, including optical film technology and precision optical technology, enabling it to provide customized solutions [14][15]. - The management team has extensive experience in the optical electronics field, with key personnel holding advanced degrees from prestigious institutions [20][21]. Market Trends - The demand for AI computing is driving the growth of the optical communication market, with OCS (Optical Circuit Switching) technology being recognized for its value in low-latency and high-bandwidth applications [10]. - The company is expanding its product offerings in emerging fields such as quantum information research, biomedical applications, and consumer optics, which are expected to contribute to revenue growth [10][29].